AbbVie
Patents, Design & Utilities
Last updated:
List of all AbbVie patents 265 in total
| Status | Patent |
|---|---|
Application | Utility: APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Filling date: 12 Sep 2025 Issue date: 11 Nov 2021 |
Grant | Utility: Prodrug modulators of the integrated stress pathway Filling date: 12 Sep 2025 Issue date: 19 Oct 2021 |
Application | Utility: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- -TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF Filling date: 12 Sep 2025 Issue date: 7 Oct 2021 |
Application | Utility: PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF Filling date: 12 Sep 2025 Issue date: 7 Oct 2021 |
Application | Utility: Dosing Regimens for Elagolix Filling date: 12 Sep 2025 Issue date: 7 Oct 2021 |
Application | Utility: MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE Filling date: 12 Sep 2025 Issue date: 23 Sep 2021 |
Grant | Design: Child-resistant medication container Filling date: 12 Sep 2025 Issue date: 21 Sep 2021 |
Grant | Design: Child-resistant medication container Filling date: 12 Sep 2025 Issue date: 21 Sep 2021 |
Grant | Utility: 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof Filling date: 12 Sep 2025 Issue date: 14 Sep 2021 |
Application | Utility: METHODS OF TREATING HEAVY MENSTRUAL BLEEDING Filling date: 12 Sep 2025 Issue date: 9 Sep 2021 |
Application | Utility: Methods of Administering Elagolix Filling date: 12 Sep 2025 Issue date: 9 Sep 2021 |
Grant | Utility: Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor Filling date: 12 Sep 2025 Issue date: 7 Sep 2021 |
Application | Utility: MODULATORS OF THE INTEGRATED STRESS PATHWAY Filling date: 12 Sep 2025 Issue date: 2 Sep 2021 |
Application | Utility: BISPECIFIC BINDING MOLECULES Filling date: 12 Sep 2025 Issue date: 19 Aug 2021 |
Application | Utility: Bromodomain Inhibitors Filling date: 12 Sep 2025 Issue date: 19 Aug 2021 |
Grant | Utility: Methods of treating Parkinson's disease Filling date: 12 Sep 2025 Issue date: 17 Aug 2021 |
Application | Utility: COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITE DEGENERATION Filling date: 12 Sep 2025 Issue date: 5 Aug 2021 |
Application | Utility: BROMODOMAIN INHIBITORS Filling date: 12 Sep 2025 Issue date: 5 Aug 2021 |
Application | Utility: PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY Filling date: 12 Sep 2025 Issue date: 29 Jul 2021 |
Application | Utility: TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB Filling date: 12 Sep 2025 Issue date: 29 Jul 2021 |
Application | Utility: APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Filling date: 12 Sep 2025 Issue date: 29 Jul 2021 |
Application | Utility: ANTIBODIES AGAINST THE RGM A PROTEIN AND USES THEREOF Filling date: 12 Sep 2025 Issue date: 29 Jul 2021 |
Application | Utility: Medicine Container, Method of Assembling the Container, and Method of Manufacturing the Container Filling date: 12 Sep 2025 Issue date: 29 Jul 2021 |
Application | Utility: APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Filling date: 12 Sep 2025 Issue date: 22 Jul 2021 |
Application | Utility: MODULATORS OF THE INTEGRATED STRESS PATHWAY Filling date: 12 Sep 2025 Issue date: 8 Jul 2021 |
Grant | Utility: Medicine container, method of assembling the container, and method of dispensing the medicine from the container Filling date: 12 Sep 2025 Issue date: 6 Jul 2021 |
Grant | Utility: Methods of treating heavy menstrual bleeding Filling date: 12 Sep 2025 Issue date: 29 Jun 2021 |
Grant | Utility: Anti-huLRRC15 antibody drug conjugates and methods for their use Filling date: 12 Sep 2025 Issue date: 29 Jun 2021 |
Application | Utility: COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR Filling date: 12 Sep 2025 Issue date: 17 Jun 2021 |
Application | Utility: PRIMARY CARBOXAMIDES AS BTK INHIBITORS Filling date: 12 Sep 2025 Issue date: 17 Jun 2021 |
Application | Utility: ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES Filling date: 12 Sep 2025 Issue date: 10 Jun 2021 |
Application | Utility: Process for Manufacturing Pibrentasvir Active Drug Substance Filling date: 12 Sep 2025 Issue date: 10 Jun 2021 |
Application | Utility: MODULATORS OF THE INTEGRATED STRESS PATHWAY Filling date: 12 Sep 2025 Issue date: 10 Jun 2021 |
Application | Utility: MODULATORS OF THE INTEGRATED STRESS PATHWAY Filling date: 12 Sep 2025 Issue date: 10 Jun 2021 |
Application | Utility: COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS Filling date: 12 Sep 2025 Issue date: 27 May 2021 |
Application | Utility: Methods of Treating Heavy Menstrual Bleeding Filling date: 12 Sep 2025 Issue date: 27 May 2021 |
Application | Utility: ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF Filling date: 12 Sep 2025 Issue date: 20 May 2021 |
Application | Utility: SLEEVE CONTAINERS FOR PACKAGING MEDICINAL PRODUCTS Filling date: 12 Sep 2025 Issue date: 13 May 2021 |
Application | Utility: DOSING REGIMENS FOR USE IN TREATING MYELOFIBROSIS AND MPN-RELATED DISORDERS WITH NAVITOCLAX Filling date: 12 Sep 2025 Issue date: 6 May 2021 |
Application | Utility: SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS Filling date: 12 Sep 2025 Issue date: 6 May 2021 |
Application | Utility: NUCLEAR RECEPTOR MODULATORS Filling date: 12 Sep 2025 Issue date: 6 May 2021 |
Application | Utility: Bromodomain Inhibitors Filling date: 12 Sep 2025 Issue date: 6 May 2021 |
Grant | Utility: Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor Filling date: 12 Sep 2025 Issue date: 4 May 2021 |
Grant | Utility: Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2- -trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof Filling date: 12 Sep 2025 Issue date: 4 May 2021 |
Application | Utility: MODULATORS OF THE INTEGRATED STRESS PATHWAY Filling date: 12 Sep 2025 Issue date: 22 Apr 2021 |
Grant | Utility: Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2- -trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Filling date: 12 Sep 2025 Issue date: 20 Apr 2021 |
Grant | Utility: Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2- -trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Filling date: 12 Sep 2025 Issue date: 20 Apr 2021 |
Application | Utility: ENZYMATIC PROCESSES FOR THE PREPARATION OF (.+-.)-2-(DIFLUOROMETHYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID AND (.+-.)-2-(VINYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID Filling date: 12 Sep 2025 Issue date: 25 Mar 2021 |
Grant | Utility: Protein tyrosine phosphatase inhibitors and methods of use thereof Filling date: 12 Sep 2025 Issue date: 23 Mar 2021 |
Application | Utility: TETRACYCLIC BROMODOMAIN INHIBITORS Filling date: 12 Sep 2025 Issue date: 11 Mar 2021 |
Showing 50 to 100 of 265 patents.